
|Articles|June 1, 2001
FDA mandates new labels for anti-fungals
Miami - The FDA last month issued a health warning concerning two popular anti-fungal drugs used to treat onychomycosis, requiring that labels for Sporanox (Janssen Pharmaceuticals) and Lamisil (Novartis) carry stronger warnings about potential liver damage. Sporanox also must warn against potential heart disease, the administration said.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Christopher Bunick, MD, PhD, on Expanding Targets in Inflammatory Skin Disease
2
Mona Shahriari, MD, FAAD, on OX40-Targeted Therapy in AD
3
When Innovation Meets Insurance Barriers With Lisa Swanson, MD
4
GLP-1s and Skin Health: Clinical Pearls From Gold and Lal
5










